Journal of computer-aided molecular design
Dec 29, 2025
Cancer immune evasion is predominantly mediated through immune checkpoint pathways, such as the PD-1/PD-L1 axis. In this mechanism, PD-L1, which is often overexpressed on tumor cells, binds to PD-1 receptors on T cells, resulting in the inhibition of...
Cell-to-cell communication through ligand-receptor (LR) interactions can fundamentally shape the tumor microenvironment and immune responses, but the full spectrum of these interactions in anti-PD-1 therapy remains unexplored. We developed a predicti...
Cancer cells express high levels of programmed cell death-ligand 1 (PD-L1) to evade immune surveillance. PD-L1 interacts with PD-1 on T cells to make them non-functional. Thus, PD-L1 and PD-1 are pivotal targets in cancer immunotherapy. While anti-PD...
BACKGROUND: With nearly one-third of patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 Tumor Proportion Score≥50% surviving beyond 5 years following first-line pembrolizumab, long-term outcomes challenge traditional paradigms of can...
INTRODUCTION: The differences among immune subtypes in coronary artery disease (CAD), their interrelationships, and the associated immune biomarkers remain incompletely understood.
BACKGROUND: Anti-programmed cell death-1 (PD-1) immunotherapy and platinum-based chemotherapy are key components of first-line treatment for advanced Gastric or Gastroesophageal Junction (G/GEJ) cancer. However, the role of immune cells infiltrating ...
Journal of the American Chemical Society
Aug 21, 2025
Detecting protein biomarkers is critical in fundamental research and clinical investigations of extracellular vesicles (EVs). Despite the prevalent use of antibodies as recognition elements, their application is often limited by challenges such as cr...
Immune checkpoint inhibitors (ICIs), either as monotherapy (ICI-Mono) or combined with chemotherapy (ICI-Chemo), improves survival in advanced non-small cell lung cancer (NSCLC). However, prospective guidance for choosing between these options remain...
BACKGROUND: PD-1/PD-L1 immunotherapy represents the primary treatment for advanced NSCLC patients; however, response rates to this therapy vary among individuals. This dual-center study aimed to integrate habitat radiomics and multi-instance deep lea...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.